Author: Yu, Ting; Tian, Chunxia; Chu, Si; Zhou, Haifeng; Zhang, Zili; Luo, Shanshan; Hu, Desheng; Fan, Heng
Title: COVIDâ€19 patients benefit from early antiviral treatment: a comparative, retrospective study Cord-id: 8920vemr Document date: 2020_6_3
ID: 8920vemr
Snippet: BACKGROUND: The outbreak of COVIDâ€19, caused by SARSâ€CoVâ€2, started in December 2019, Wuhan, China. We aimed to figure out the timeâ€point and duration of using antiviral drugs for receiving the maximal effects in patients with COVIDâ€19. METHODS: In this study, we enrolled 129 confirmed COVIDâ€19 mild to moderate patients who had been treated with antiviral drugs during their hospitalization in Wuhan Union Hospital China. The patients were divided into early antiviral treatment group a
Document: BACKGROUND: The outbreak of COVIDâ€19, caused by SARSâ€CoVâ€2, started in December 2019, Wuhan, China. We aimed to figure out the timeâ€point and duration of using antiviral drugs for receiving the maximal effects in patients with COVIDâ€19. METHODS: In this study, we enrolled 129 confirmed COVIDâ€19 mild to moderate patients who had been treated with antiviral drugs during their hospitalization in Wuhan Union Hospital China. The patients were divided into early antiviral treatment group and late antiviral treatment group. The demographic data, laboratory tests, the virus clearance time, chest computed tomography (CT) scans, etc. were extracted, calculated and compared between two groups. RESULTS: Our data showed that the median time from illness onset to initiation of antiviral treatment was 6 days in all patients. The group with early antiviral treatment demonstrated 7 days shorter in the virus clearance time when compared to the group with late antiviral treatment. After virus clearance, the group with early antiviral treatment showed milder illness than the group with late antiviral treatment. CONCLUSIONS: Early antiviral treatment could effectively shorten the virus clearance time, and prevent the rapid progression of COVIDâ€19. Therefore, the COVIDâ€19 patients should receive combined therapies with antiviral treatment at early stage. This article is protected by copyright. All rights reserved.
Search related documents:
Co phrase search for related documents- absolute count and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- absolute count and admission group: 1, 2, 3, 4
- absolute count and lopinavir ritonavir: 1
- absolute count and lung infection: 1
- accepted article and acute respiratory syndrome: 1, 2, 3, 4, 5
- action mode and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- action mode and lopinavir ritonavir: 1, 2, 3, 4
- action mode and lopinavir ritonavir treatment: 1
- action mode and lung infection: 1, 2
- action mode mainly and acute respiratory syndrome: 1
- acute respiratory syndrome and admission group: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and admission patient occur: 1
- acute respiratory syndrome and long term presence: 1, 2, 3, 4, 5, 6
- acute respiratory syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and lopinavir ritonavir treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and lung infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- admission group and lopinavir ritonavir: 1, 2, 3, 4, 5, 6
- admission group and lopinavir ritonavir treatment: 1
- admission group and lung infection: 1, 2
Co phrase search for related documents, hyperlinks ordered by date